Uta Kiltz, Petros Sfikakis, Andreas Bounas, Nicola Gullick, Eric Lespessailles, Jan Brandt Jürgens, Rasho Rashkov, Barbara Schulz, Weibin Bao, Piotr Jagiello, Karl Gaffney
Abstract or description:Background/Purpose
Real-world data on long-term use of secukinumab complements clinical trial findings by providing insights from diverse patients in routine clinical settings. SERENA (CAIN457A3403) was a non-interventional, prospective study conducted across 19 primarily European countries for up to 5 years in patients with moderate to severe chronic plaque psoriasis, active psoriatic arthritis (PsA) or radiographic axial spondyloarthritis (r-axSpA), who had received secukinumab for ≥16 weeks before enrollment. Here, we report the final 5-year results of retention and effectiveness of secukinumab in patients with active PsA or r-axSpA from the study.
Methods:
Secukinumab retention rate was derived from Kaplan-Meier estimates for the proportion of patients who had been treated with secukinumab at years 1, 2, 3, 4 and 5. Effectiveness assessments included swollen joint count (SJC) and tender joint count (TJC) in patients with PsA, Patient Global Assessment (PtGA) of disease activity of Numeric Rating Scale (NRS ≤2) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score in patients with r-axSpA, up to 5 years.
Results:
Overall, 522 patients with PsA and 474 patients with r-axSpA were included in the analysis. The mean age at inclusion was 52.5 years in the PsA group and 46.5 years in the r-axSpA group, with 44.8% and 60.5% being male, respectively. Mean body mass index of 28.7 kg/m2 was observed in the PsA group and 27.0 kg/m2 in the
r-axSpA group. Disease duration at enrollment was 8.6 ± 7.4 years in PsA and 9.8 ± 9.5 years in r-axSpA respectively. Overall, 68.6% and 64.6% of patients with PsA and r-axSpA had undergone bDMARDs (biologic disease-modifying antirheumatic drugs) treatment prior to secukinumab, respectively. Before inclusion in the study, the patients had been receiving secukinumab treatment for an average of 1 year. After inclusion in the study, the treatment retention rates at years 1, 2, 3, 4 and 5 for PsA group were 86.9%, 75.8%, 67.9%, 60.8% and 55.7%, respectively. Similarly, the treatment retention rates at years 1, 2, 3, 4 and 5 for r-axSpA group were 86.2%, 78.8%, 72.1%, 65.2% and 61.1%, respectively. The most common reasons for discontinuation in PsA and r-axSpA were lack of efficacy (27.2% and 17.7%, respectively), patient decision (11.9% and 8.6%), lost to follow-up (5.7% and 6.1%) and adverse events (3.1% and 7.2%). The proportion of patients with TJC ≤1 was 75.7% at year 1 and 81.0% at year 5; the proportion of patients with a SJC ≤1 response was 86.5% at year 1 and 90.0% at year 5 in the PsA group. BASDAI improved in r-axSpA group through the 5 years. The proportion of patients with PtGA NRS ≤2 was 32.5% at year 1 and 46.1% at year 5 in the r-axSpA group.
Conclusion:
Secukinumab retention rates were high with sustained effectiveness in patients with PsA and r-axSpA during 5-year follow-up in a prospective real-world setting.
Reprinted from the American College of Rheumatology (ACR) Convergence held November 14–19, 2024 in Washington, DC, United States. The American College of Rheumatology does not guarantee, warrant, or endorse any commercial products or services. Reprinted by Novartis US Medical Affairs.
Novartis has paid RheumNow to host this content. Novartis is solely responsible for all the written content within this presentation.
© 2025 Novartis. All rights reserved. 5/25 FA-11375352
Uta Kiltz, Petros Sfikakis, Andreas Bounas, Nicola Gullick, Eric Lespessailles, Jan Brandt Jürgens, Rasho Rashkov, Barbara Schulz, Weibin Bao, Piotr Jagiello, Karl Gaffney
Abstract or description:Background/Purpose
Real-world data on long-term use of secukinumab complements clinical trial findings by providing insights from diverse patients in routine clinical settings. SERENA (CAIN457A3403) was a non-interventional, prospective study conducted across 19 primarily European countries for up to 5 years in patients with moderate to severe chronic plaque psoriasis, active psoriatic arthritis (PsA) or radiographic axial spondyloarthritis (r-axSpA), who had received secukinumab for ≥16 weeks before enrollment. Here, we report the final 5-year results of retention and effectiveness of secukinumab in patients with active PsA or r-axSpA from the study.
Methods:
Secukinumab retention rate was derived from Kaplan-Meier estimates for the proportion of patients who had been treated with secukinumab at years 1, 2, 3, 4 and 5. Effectiveness assessments included swollen joint count (SJC) and tender joint count (TJC) in patients with PsA, Patient Global Assessment (PtGA) of disease activity of Numeric Rating Scale (NRS ≤2) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score in patients with r-axSpA, up to 5 years.
Results:
Overall, 522 patients with PsA and 474 patients with r-axSpA were included in the analysis. The mean age at inclusion was 52.5 years in the PsA group and 46.5 years in the r-axSpA group, with 44.8% and 60.5% being male, respectively. Mean body mass index of 28.7 kg/m2 was observed in the PsA group and 27.0 kg/m2 in the
r-axSpA group. Disease duration at enrollment was 8.6 ± 7.4 years in PsA and 9.8 ± 9.5 years in r-axSpA respectively. Overall, 68.6% and 64.6% of patients with PsA and r-axSpA had undergone bDMARDs (biologic disease-modifying antirheumatic drugs) treatment prior to secukinumab, respectively. Before inclusion in the study, the patients had been receiving secukinumab treatment for an average of 1 year. After inclusion in the study, the treatment retention rates at years 1, 2, 3, 4 and 5 for PsA group were 86.9%, 75.8%, 67.9%, 60.8% and 55.7%, respectively. Similarly, the treatment retention rates at years 1, 2, 3, 4 and 5 for r-axSpA group were 86.2%, 78.8%, 72.1%, 65.2% and 61.1%, respectively. The most common reasons for discontinuation in PsA and r-axSpA were lack of efficacy (27.2% and 17.7%, respectively), patient decision (11.9% and 8.6%), lost to follow-up (5.7% and 6.1%) and adverse events (3.1% and 7.2%). The proportion of patients with TJC ≤1 was 75.7% at year 1 and 81.0% at year 5; the proportion of patients with a SJC ≤1 response was 86.5% at year 1 and 90.0% at year 5 in the PsA group. BASDAI improved in r-axSpA group through the 5 years. The proportion of patients with PtGA NRS ≤2 was 32.5% at year 1 and 46.1% at year 5 in the r-axSpA group.
Conclusion:
Secukinumab retention rates were high with sustained effectiveness in patients with PsA and r-axSpA during 5-year follow-up in a prospective real-world setting.
Reprinted from the American College of Rheumatology (ACR) Convergence held November 14–19, 2024 in Washington, DC, United States. The American College of Rheumatology does not guarantee, warrant, or endorse any commercial products or services. Reprinted by Novartis US Medical Affairs.
Novartis has paid RheumNow to host this content. Novartis is solely responsible for all the written content within this presentation.
© 2025 Novartis. All rights reserved. 5/25 FA-11375352
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.